𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Disease severity and domain-specific arthritis self-efficacy: Relationships to pain and functioning in patients with rheumatoid arthritis

✍ Scribed by Tamara J. Somers; Rebecca A. Shelby; Francis J. Keefe; Neha Godiwala; Mark A. Lumley; Angelia Mosley-Williams; John R. Rice; David Caldwell


Publisher
Wiley (John Wiley & Sons)
Year
2010
Tongue
English
Weight
105 KB
Volume
62
Category
Article
ISSN
2151-464X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Objective

To examine the degree to which disease severity and domains of self‐efficacy (pain, function, and other symptoms) explain pain and functioning in rheumatoid arthritis (RA) patients.

Methods

Patients (n = 263) completed the Arthritis Impact Measurement Scales 2 to assess pain and functioning (physical, affective, and social), the Arthritis Self‐Efficacy Scale to assess 3 self‐efficacy domains (pain, physical function, and other). Disease severity was assessed with C‐reactive protein level, physician's rating, and abnormal joint count. Structural equation modeling was used to examine 3 hypotheses: does disease severity have a direct relationship with pain and each area of functioning, does disease severity have a direct relationship with each arthritis self‐efficacy domain, and do the self‐efficacy domains mediate the relationship between disease severity and RA pain and each area of functioning.

Results

Disease severity was related to pain, physical functioning, and each self‐efficacy domain (β = 0.28–0.56, P < 0.001). Each self‐efficacy domain was related to its respective domain of functioning (e.g., self‐efficacy for pain was related to pain; β = 0.36–0.54, P < 0.001). Self‐efficacy mediated the relationship between disease severity and pain and functioning (β = 0.12–0.19, P < 0.001). Self‐efficacy for pain control and to perform functional tasks accounted for 32–42% of disease severity's total effect on their respective outcomes (e.g., self‐efficacy for pain control accounted for 32% of disease severity's total effect on pain). Variance accounted for by the total model was 52% for pain, 53% for physical functioning, and 44% for affective and social functioning.

Conclusion

Disease severity and self‐efficacy both impact RA functioning, and intervening in these areas may lead to better outcomes.


📜 SIMILAR VOLUMES


Development of antiinfliximab antibodies
✍ Gerrit Jan Wolbink; Marijn Vis; Willem Lems; Alexandre E. Voskuyl; Els De Groot; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 1 views

## Abstract ## Objective Treatment of patients with infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, may result in the formation of infliximab‐specific IgG antibodies. This study evaluated the clinical significance of these antibodies in patients with rheumatoid arthr

The relationship between disease activit
✍ Paco M. J. Welsing; Robert B. M. Landewé; Piet L. C. M. Van Riel; Maarten Boers; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 2 views

## Abstract ## Objective Radiologic progression in rheumatoid arthritis (RA) is considered the consequence of persistent inflammatory activity. To determine whether a change in disease activity is related to a change in radiologic progression in individual patients, we investigated the longitudina

Association of autoimmunity to peptidyl
✍ Michelle L. Harris; Erika Darrah; Gordon K. Lam; Susan J. Bartlett; Jon T. Giles 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 237 KB

## Abstract ## Objective Protein citrullination is an important posttranslational modification recognized by rheumatoid arthritis (RA)–specific autoantibodies. One of the citrullinating enzymes, peptidyl arginine deiminase type 4 (PAD‐4), is genetically associated with development of RA in some po